Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Resistant Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015

Resistant Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Resistant Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Resistant Pseudomonas Aeruginosa Infections-Pipeline Review, H1 2015', provides an overview of the Resistant Pseudomonas Aeruginosa Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas Aeruginosa Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Resistant Pseudomonas Aeruginosa Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Resistant Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Resistant Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas Aeruginosa Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Resistant Pseudomonas Aeruginosa Infections Overview 8

Therapeutics Development 9

Pipeline Products for Resistant Pseudomonas Aeruginosa Infections-Overview 9

Pipeline Products for Resistant Pseudomonas Aeruginosa Infections-Comparative Analysis 10

Resistant Pseudomonas Aeruginosa Infections-Therapeutics under Development by Companies 11

Resistant Pseudomonas Aeruginosa Infections-Therapeutics under Investigation by Universities/Institutes 12

Resistant Pseudomonas Aeruginosa Infections-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Resistant Pseudomonas Aeruginosa Infections-Products under Development by Companies 15

Resistant Pseudomonas Aeruginosa Infections-Products under Investigation by Universities/Institutes 16

Resistant Pseudomonas Aeruginosa Infections-Companies Involved in Therapeutics Development 17

Achaogen Inc. 17

AstraZeneca PLC 18

Biolytics Pharma 19

CSA Biotechnologies LLC 20

LegoChem Biosciences, Inc 21

Melinta Therapeutics, Inc 22

Microbion Corporation 23

Phico Therapeutics Ltd. 24

Phylogica Limited 25

Shionogi & Co., Ltd. 26

Zambon Company S.p.A. 27

Resistant Pseudomonas Aeruginosa Infections-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Combination Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

ACHN-975 Prodrug-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Biologic for Pseudomonas Aeruginosa Infection-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Cephalosporin + Beta-Lactamase Inhibitor-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

CSA-13-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

G-10-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

LCB-100200-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Monoclonal Antibodies for Gram-Negative Bacterial Infections-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

PT-3.33-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

RXP-763-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

RXP-766-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

RXP-770-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

RXP-792-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

RXP-793-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

RXP-808-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

RXP-873-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

S-649266-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecule for Chronic Wound Infection and Bacterial Infections-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecules for Gram-Negative Bacterial Infections-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules for Multi-Drug Resistant Bacterial Infections-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ZP-046-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Resistant Pseudomonas Aeruginosa Infections-Recent Pipeline Updates 62

Resistant Pseudomonas Aeruginosa Infections-Dormant Projects 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections, H1 2015 9

Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Achaogen Inc., H1 2015 17

Resistant Pseudomonas Aeruginosa Infections-Pipeline by AstraZeneca PLC, H1 2015 18

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Biolytics Pharma, H1 2015 19

Resistant Pseudomonas Aeruginosa Infections-Pipeline by CSA Biotechnologies LLC , H1 2015 20

Resistant Pseudomonas Aeruginosa Infections-Pipeline by LegoChem Biosciences, Inc, H1 2015 21

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 22

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Microbion Corporation, H1 2015 23

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Phico Therapeutics Ltd., H1 2015 24

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Phylogica Limited, H1 2015 25

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Shionogi & Co., Ltd., H1 2015 26

Resistant Pseudomonas Aeruginosa Infections-Pipeline by Zambon Company S.p.A., H1 2015 27

Assessment by Monotherapy Products, H1 2015 28

Assessment by Combination Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Resistant Pseudomonas Aeruginosa Infections Therapeutics-Recent Pipeline Updates, H1 2015 62

Resistant Pseudomonas Aeruginosa Infections-Dormant Projects, H1 2015 65

List of Figures

Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections, H1 2015 9

Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achaogen Inc.

AstraZeneca PLC

Biolytics Pharma

CSA Biotechnologies LLC

LegoChem Biosciences, Inc

Melinta Therapeutics, Inc

Microbion Corporation

Phico Therapeutics Ltd.

Phylogica Limited

Shionogi & Co., Ltd.

Zambon Company S.p.A.

Resistant Pseudomonas Aeruginosa Infections Therapeutic Products under Development, Key Players in Resistant Pseudomonas Aeruginosa Infections Therapeutics, Resistant Pseudomonas Aeruginosa Infections Pipeline Overview, Resistant Pseudomonas Aeruginosa Infections Pipeline, Resistant Pseudomonas Aeruginosa Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com